Table 1 Patient's GP Read codes during the 3 month recall period
From: HERALD (Health Economics using Routine Anonymised Linked Data)
GP Event Date | (sl) GP Read Codes: Descriptions | Comment |
|---|---|---|
10 August | (i) fh1k: PREMIQUE 0.625 mg/5 mg tablets; (ii) b211: BEMDROFLUAZIDE 2.5 mg tablets; (iii) b211: BENDROFLUMETHIAZIDE 2.5 mg tablets; (iv) bxd2: SIMVASTATIN 20 mg tablets; (v) Bd35: ATENONOL 50 mg tablets | GP visit /Prescription collection |
31 August | 1969: Abdominal pain | System reporting of A&E admission on 30 August |
01 September | Discharge Summary | System reporting of A&E discharge summary (ref: 30 August A&E admission) |
17 September | (i) fh1k: PREMIQUE 0.625 mg/5 mg tablets; (ii) b211: BEMDROFLUAZIDE 2.5 mg tablets; (iii) b211: BENDROFLUMETHIAZIDE 2.5 mg tablets; (iv) bxd2: SIMVASTATIN 20 mg tablets; (v) Bd35: ATENONOL 50 mg tablets; (vi) j2ck: NAPROXEN 250 mg e/c tablets; (vii) 246..: O/E blood pressure; (viii) di21: PARACETAMOL 500 mg; (ix) 8B4: Repeat Prescription. | GP Visit |
23 September | (i) 52...: Plain Radiography; (ii) 52....:Plain X-Ray | GP visit |
07 October | (i) bd35: ATENONOL 50 mg tablets; (ii) b211: BEMDROFLUAZIDE 2.5 mg tablets; (iii) bxd2: SIMVASTATIN 20 mg tablets; (iv) 8CB..: Had a chinwag with patient; (v) 8CB..: Had a discussion with patient. | GP visit |
11 October | 9 N4..: Failed encounter | No visit |
28 October | (i) b211: BEMDROFLUAZIDE 2.5 mg tablets; (ii) b211: BENDROFLUMETHIAZIDE 2.5 mg tablets; (iii) bxd2: SIMVASTATIN 20 mg tablets; (iv) Bd35: ATENONOL 50 mg tablets (v) j2ck: NAPROXEN 250 mg e/c tablets | GP visit/prescription collection |
30 October | (i) j2ck: NAPROXEN 25 mg e/c tablets | Prescription collection |
04 November | (i) 9 N36: Letter from specialist; (ii) Letter from consultant | No visit |